Treatment of Ulcerative Colitis with 6 or More Bowel Movements Daily (Acute Severe Presentation)
Clinical Scenario
Acute severe ulcerative colitis (ASUC) is a medical emergency requiring prompt inpatient management. It is defined by a markedly elevated stool frequency combined with objective systemic signs of toxicity — distinct from moderate or ambulatory disease flares.
Diagnostic Criteria for ASUC
This protocol applies when a patient with ulcerative colitis has 6 or more bowel movements daily accompanied by at least one of the following systemic signs of toxicity:
- Tachycardia
- Fever
- Anemia — hemoglobin below 10.5 g/dL
- Elevated inflammatory markers — ESR above 30 mm/hr
Treatment Approach (Overview)
The primary induction strategy for hospitalised ASUC patients centres on intravenous corticosteroids, combined with pharmacologic thromboprophylaxis. When specific co-infections are identified, targeted antimicrobial therapy is incorporated without discontinuing the primary treatment. The complete regimen — including agent selection, schedule, co-infection management, and response-assessment protocol — is detailed in the full structured protocol.
Treatment goals: Decreasing stool frequency, absence of rectal bleeding, and falling C-reactive protein — assessed over 3–5 days of therapy.
References
DOI: 10.14309/ajg.0000000000003463
ASUC is defined as the presence of 6 or more bowel movements daily accompanied by at least one systemic sign of toxicity including tachycardia, fever, anemia (hemoglobin <10.5 g/dL), or elevated inflammatory markers (ESR >30 mm/hr).
In patients with ASUC, we recommend a total of 60 mg/d of methylprednisolone or hydrocortisone 100 mg 3 or 4 times per day to induce remission.
In patients with ASUC, we recommend pharmacologic DVT prophylaxis as compared with no prophylaxis to prevent VTE.
Thromboprophylaxis with low molecular weight heparin should be given to all hospitalized patients with acute colitis.
Treatment of CDI in hospitalized patients with ASUC should follow the Infectious Disease Society of America Guidelines, which suggest vancomycin or fidaxomicin first-line therapy.
When treating CMV colitis, the most commonly studied agent is ganciclovir, administered initially intravenously and subsequently orally for a 14-day course, with a response rate around 70%.
Oral therapy with valganciclovir may also be appropriate in selected patients.
Response in patients with acute severe UC should be monitored using stool frequency, rectal bleeding, physical examination, vital signs, and serial CRP measurements.
Response to IVCS is usually apparent within 3–5 days of initiation and additional response after 7 days is unlikely.
View source ↗